Categories
Alembic Pharmaceuticals Limited — Updates, 25-04-2026: Press Release
25-04-2026 · 11:58 am
Alembic Pharma secures USFDA Final Approval for Fingolimod Capsules 0.5 mg. This generic equivalent targets an estimated US$ 145 million market, significantly strengthening the company's US product pipeline.
No comments yet. Be the first to comment!